Neuroprotective Effects of Quercetin in Neonatal Hypoxic-Ischemic Brain Injury: A Meta-analysis
American Journal of Perinatology, cilt.42, sa.16, ss.2203-2208, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 42 Sayı: 16
- Basım Tarihi: 2025
- Doi Numarası: 10.1055/a-2578-1875
- Dergi Adı: American Journal of Perinatology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.2203-2208
- Anahtar Kelimeler: quercetin, neonatal hypoxic-ischemic brain injury, neuroprotection, meta-analysis, therapeutic hypothermia
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective This study assesses the neuroprotective potential of quercetin in preclinical models of neonatal hypoxic-ischemic brain injury (HIBI) and its role as a possible enhancer of therapeutic hypothermia. Study Design A systematic review of 8 preclinical studies was conducted per PRISMA guidelines, sourced from PubMed, Scopus, and Web of Science, with a random-effects meta-analysis. Results Quercetin significantly lowered infarct volume, seizure susceptibility, and inflammation (pooled standardized mean differences [SMD] ¼ 1.29; 95% confidence interval [CI]: 1.00–1.58; p < 0.001). Higher doses (>30 mg/kg, SMD ¼ 1.65) and intraperitoneal (IP) administration (SMD ¼ 1.42) outperformed lower doses or intravenous (IV) routes (SMD ¼ 0.95). Rat models showed greater benefits (SMD ¼ 1.38) than piglets (SMD ¼ 0.85). Moderate heterogeneity (I2 ¼ 45%) was noted, but sensitivity analysis confirmed robustness (SMD ¼ 1.20). Publication bias was minimal (p ¼ 0.12). Conclusion Quercetin offers notable neuroprotection in neonatal HIBI, with an optimal 40 mg/kg IP dose, suggesting it could complement hypothermia. Limited bioavailability and lack of long-term data call for further research in advanced models.